CBAK Energy Technology, Inc. is a China-based manufacturer of lithium-ion and sodium-ion rechargeable battery cells, with facilities in Dalian and Nanjing. Coverage of the stock is unusually thin. TipRanks currently lists zero analysts actively covering the name, and aggregators such as Yahoo Finance and Investing.com show a single 12-month price target of $1.50. That figure traces to Zacks Small-Cap Research (analyst Brian Lantier), which has maintained a $1.50 valuation target across several reports and reaffirmed it in February 2026.
With only one attributable, current target rather than a genuine multi-analyst consensus, this article does not present $1.50 as an official "analyst consensus." Instead, $1.50 is treated as a realistic price objective that is being discussed publicly in research reports and data platforms. For context, the published single-target range is $1.50 to $1.50, so there is no meaningful spread among analysts to weigh. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The stock last closed near $1.05, within a 52-week range of roughly $0.46 to $1.55. Reaching $1.50 would require an advance of about 43% from that level, a substantial move for a small-cap stock with a market capitalization near $93 million. The path would likely depend on the company converting its top-line momentum into sustainable profitability as newly installed capacity ramps up.
The company's revenue has been growing quickly. In its most recent quarterly update, consolidated revenue rose roughly 132% year over year to about $58.8 million, and trailing twelve-month revenue growth is around 50%. Management has guided toward record consolidated sales as new capacity comes online, including the Dalian 40135 line (2.3 GWh) commissioned at the end of 2025 and two additional Nanjing Phase II lines adding roughly 3.0 GWh. The raw-materials subsidiary, Hitrans, has also improved, with revenue up about 123% year over year to roughly $89 million, and cathode-material price hikes in China could provide a tailwind. From what I see, these capacity additions remain central to the outlook.
The principal obstacle is profitability. Full-year 2025 gross margin fell to about 9.4% from 23.7% in 2024, reflecting higher unit costs and lower yields during capacity transitions, and the company has continued to post net losses. Balance-sheet strain is another concern: the company's independent auditors have expressed substantial doubt about its ability to continue as a going concern. Any delay in the Dalian or Nanjing ramp-up, further margin compression, or renewed U.S.-China trade friction could keep the stock well below $1.50.
The $0.46 area marks the 52-week low and a key support zone, while $1.55 is the 52-week high and a significant resistance level just above the $1.50 objective. The $1.00 round-number level is a psychological zone that the stock has traded around. A durable move toward $1.50 would require the shares to first hold above $1.00 and then challenge the prior high near $1.55.
The $1.50 figure reflects a research-horizon valuation, commonly viewed over roughly a 12-month window, though no firm timeline is guaranteed. Investors should watch the upcoming earnings release, guidance on gross-margin recovery and capacity ramp-up timing, any news on the Anker Innovations partnership, and updates on the going-concern assessment. Changes to the single published target, or the addition of new coverage, would also be worth monitoring. I’m watching this closely as earnings approach.
Can CBAT reach $1.50? The target implies a substantial move of about 43% from the current price, and it rests on a single, publicly discussed valuation rather than a broad analyst consensus. Rapid revenue growth, a major capacity expansion, and a recovering raw-materials segment argue in its favor, while margin compression, persistent losses, and a going-concern warning are significant counterweights. The stock's own 52-week high of $1.55 shows the level is not unprecedented, but reaching and holding $1.50 would likely require evidence that new capacity is converting into durable profitability. No outcome is guaranteed, and investors should monitor earnings, margins, and the balance sheet closely.
For traders who want a systematic way to track names like CBAT, Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs and generate Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. The tool is designed to help traders discover opportunities, monitor existing positions, and spot shifting trends more efficiently than manual screening alone. Exploring these signals can be a useful complement to fundamental research. In my experience, integrating such tools has helped refine timing around earnings and capacity updates.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
CBAT moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend. In 39 of 43 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The 10-day moving average for CBAT crossed bearishly below the 50-day moving average on October 22, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 18 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 67%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CBAT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for CBAT entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where CBAT's RSI Oscillator exited the oversold zone, 27 of 39 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on CBAT as a result. In 68 of 98 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.
The Moving Average Convergence Divergence (MACD) for CBAT just turned positive on October 30, 2026. Looking at past instances where CBAT's MACD turned positive, the stock continued to rise in 32 of 43 cases over the following month. The odds of a continued upward trend are 74%.
Following a +6.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where CBAT advanced for three days, in 180 of 232 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.881) is normal, around the industry mean (2.765). P/E Ratio (-5.806) is within average values for comparable stocks, (13.467). Projected Growth (PEG Ratio) (0.050) is also within normal values, averaging (2.910). Dividend Yield (0.000) settles around the average of (0.091) among similar stocks. P/S Ratio (0.395) is also within normal values, averaging (9.055).
The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. CBAT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CBAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of lithium batteries and related renewable energy products
Industry ElectricalProducts